Treatment of Diarrhea-Predominant Irritable Bowel Syndrome With Mesalazine and/or Saccharomyces Boulardii

Abstract

-Results -Compared to baseline, there were statistically significant reduction of symptom score after 30 th day therapy in all three groups: MG (P<0.0001); MSbG (P<0.0001) and in SbG (P = 0.003). There were statistically significant differences in the symptom score at 30 th day therapy of the MG, MSbG and SbG groups (P = 0.03). There were no statistical differences between MSbG and MG symptom score at 30th day therapy (P = 0.9). Conclusions -The use of mesalazine alone, Saccharomyces boulardii alone or combined treatment with mesalasine and Saccaromyces boulardii improved IBS-D symptoms. The improvement of the symptom score was greater with mesalazine alone or combined with Sb as compared with Sb treatment alone. These preliminary results suggest that mezalazine may be useful in treatment of IBS-d patients, and warrant further larger studies. HEADINGS -Irritable bowel syndrome. Diarrhea. Mesalamine. Saccharomyces boulardii.

Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS

“…Our data are consistent with available clinical studies reporting favorable effects of S . boulardii CNCM I-745 supplementation on the gastrointestinal functional anomalies observed in IBS patients [16,34,35,36]. In 2008, Swidsinski et al .…”

“…On the other hand, Bafutto and colleagues reported that S . boulardii significantly improved GI symptoms in IBS patients and Abbas and colleagues demonstrated an improvement of quality of live and a significant reduction in mucosal inflammatory cytokines [34,36]. Interestingly, recent studies reported the effectiveness of other probiotic yeasts in IBS patients.…”

Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome

“…Saccharomyces boulardii, used in food processing and for the treatment of IBS, was shown to significantly improve IBS symptom scores from baseline in patients with IBS-D (n = 12) after 30 days of treatment (P = 0.003) [84]. A metaanalysis of individual data from 579 patients with IBS included in two randomized, double-blind, placebo-controlled studies of Saccharomyces cerevisiae CNCM I-3856 showed that abdominal pain/discomfort and bloating were significantly improved with probiotic therapy versus placebo during month 2 of treatment (P = 0.01, for both comparisons) [85].…”

Uso de probióticos en síndrome de intestino irritable y enfermedad inflamatoria intestinal: una revisión de la literatura

“…El estudio de Bafutto en Brasil, con 53 pacientes, comparó el uso de mesalazina 800 mg/día sola o asociada con 200 mg de Saccharomyces boulardii por 30 días y reportó mejoría en el dolor abdominal y deposiciones en pacientes con terapia combinada (p <0,05) (13).…”

“…con una mejoría clínica hasta de 80% en pacientes tratados (15,17,34,37). En cuanto al SII, en la mayoría de artículos estudiados se establece una asociación entre el consumo de probióticos y la mejoría subjetiva y objetiva de sus síntomas cardinales, valorados tanto por cuestionarios subjetivos como por la escala de Bristol (calidad de deposiciones) (13,17,32).…”